Brokerages Set InflaRx N.V. (NASDAQ:IFRX) Price Target at $7.00

Shares of InflaRx N.V. (NASDAQ:IFRX) have been given a consensus rating of “Moderate Buy” by the seven ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $7.00.

IFRX has been the topic of several recent analyst reports. Oppenheimer initiated coverage on InflaRx in a research report on Friday, April 24th. They set an “outperform” rating and a $5.00 price target on the stock. Cantor Fitzgerald boosted their price target on InflaRx from $2.00 to $4.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Wall Street Zen raised InflaRx from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. HC Wainwright boosted their price target on InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Finally, Raymond James Financial raised InflaRx from an “outperform” rating to a “strong-buy” rating and boosted their price target for the stock from $7.00 to $9.00 in a research report on Wednesday, May 13th.

InflaRx Stock Down 1.2%

IFRX stock opened at $1.60 on Wednesday. The company has a market cap of $115.66 million, a price-to-earnings ratio of -2.25 and a beta of 2.42. InflaRx has a twelve month low of $0.74 and a twelve month high of $2.95. The business has a 50 day moving average price of $1.91 and a two-hundred day moving average price of $1.31.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.08. On average, equities research analysts anticipate that InflaRx will post -0.4 EPS for the current fiscal year.

Institutional Trading of InflaRx

Several institutional investors and hedge funds have recently bought and sold shares of the business. ADAR1 Capital Management LLC bought a new stake in InflaRx in the first quarter valued at approximately $142,000. XTX Topco Ltd bought a new stake in InflaRx in the fourth quarter valued at approximately $135,000. Suvretta Capital Management LLC raised its stake in InflaRx by 22.4% in the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after buying an additional 1,450,000 shares during the period. Quadrature Capital Ltd bought a new stake in InflaRx in the fourth quarter valued at approximately $104,000. Finally, Eversept Partners LP lifted its stake in shares of InflaRx by 1.5% during the 4th quarter. Eversept Partners LP now owns 1,757,312 shares of the company’s stock worth $1,775,000 after buying an additional 26,677 shares during the last quarter. Institutional investors own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.